清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Phenotyping in Cancer Pain: Bridging the Gap to Personalized Pain Medicine

作者
Indubala Maurya
出处
期刊:Indian Journal of Pain (Indpain) [Medknow]
卷期号:39 (1): 1-2 被引量:1
标识
DOI:10.4103/ijpn.ijpn_8_25
摘要

INTRODUCTION Cancer pain remains a multifaceted clinical challenge. Despite advancements in pharmacological and interventional pain management, cancer pain remains under-recognized and undertreated, leading to poor functional status, quality of life, and increased morbidity. Effective pain management requires the identification of underlying pain mechanisms. Applying the concept of precision pain medicine for cancer pain management is by classifying pain mechanisms into three major pain phenotypes, as defined by the International Association for the Study of Pain (IASP), i.e., nociceptive, neuropathic, and nociplastic pain. Pain phenotyping offers a framework to plan pain management strategies based on distinct biological, sensory, and psychological profiles, which can revolutionize cancer pain management. Integrating this personalized approach with treatment strategies takes steps beyond the traditional concept of the “one-size-fits-all” model. This article explores the concept of pain phenotyping and its role in enhancing personalized cancer pain treatment.[1,2] CANCER PAIN PHENOTYPING During surgery, chemotherapy, and radiotherapy, most of the cancer pain is nociceptive and/or neuropathic type. Nociceptive pain, caused by tissue inflammation and damage, is often presented with painful movement. Neuropathic pain is commonly encountered in postcancer treatment or cancer survivors. Patients present with sensory and motor symptoms, including numbness, tingling, weakness, and burning pain. Neuropathic pain is triggered by nerve damage due to localized nerve compression/invasion, peripheral nerve damage during the cancer surgery (e.g. the intercostobrachial nerve during axillary lymph node dissection), chemotherapy induced and radiation induced. Cancer patients on taxane or platinum-based chemotherapy are most likely to experience chemotherapy-induced peripheral neuropathy.[3,4] The third mechanism for pain, in addition to nociceptive and neuropathic pain, is “nociplastic” pain, which was introduced in 2017. Previously, the term “central sensitisation” was broadly used for any persistent, widespread chronic pain. The IASP defines nociplastic pain as “pain that arises from altered nociception despite no clear evidence of actual or threatened tissue damage causing the activation of peripheral nociceptors or evidence for disease or lesion of the somatosensory system causing the pain.” Whereas the pain mechanisms underlying nociceptive and neuropathic pain are apparent, the underlying mechanisms for nociplastic pain are not entirely understood; central sensitization and altered pain modulation, i.e., decreased inhibition and increased facilitation, play essential roles. Many recent studies suggest that nociplastic pain is present in a subgroup of cancer patients. The patient with nociplastic pain complains of widespread multifocal pain, fatigue, poor sleep, depressed mood, and sensitivity to sensory stimuli. The diagnosis of nociplastic pain is often delayed due to nonspecific symptoms. The 2021 IASP released clinical criteria and grading system for musculoskeletal system-related nociplastic pain, which facilitates early identification of patients according to pain phenotype. These criteria have replaced the IASP 2014 clinical criteria for predominant central sensitization pain.[2,5] The concept of nociplastic pain applies not only to chronic noncancer pain but also to patients with cancer. Recently, Cancer Pain Phenotyping (CANPPHE) Network, an international and interdisciplinary group, applied IASP 2021 clinical criteria for nociplastic pain for cancer pain. It is a seven-step clinical decision-making tree to diagnose postcancer nociplastic pain, including (1) postcancer pain >3 months, (2) regional distribution, (3) entirely nociceptive pain, (4) entirely neuropathic pain, (5) evoked pain sensitivity phenomenon (e.g., static or dynamic mechanical allodynia, heat or cold allodynia), (6) history of pain sensitivity, and (7) at least one comorbid condition. It guides pain physicians/oncologists in identifying the pain phenotype in cancer patients and tailoring pain management accordingly, which is seemingly a step toward precision pain medicine for cancer patients.[6] Pain phenotyping in cancer patients is essential due to various reasons. Neuropathic and mixed cancer pain are more challenging to treat than pure nociceptive pain. The selection of pain management needs to consider the pain phenotype as mechanism-based pain management, which has better outcomes than symptomatic or diagnosis-based management.[7,8] However, the management of nociplastic pain is challenging, as pain complaints are often vague and associated with subjective symptoms. Specific clinical findings are absent. Thus, nociplastic pain management is frustrating for both pain physicians and patients. Patients with nociplastic components are at higher risk for opioid-induced hyperalgesia. Individualized approaches for multimodal therapies, including psychotherapies, psychotropic drugs (such as antidepressants and gabapentinoids), and physical exercise should be considered.[9,10] Classifying cancer pain to one phenotype group is an oversimplification, as mixed-pain symptoms with a substantial overlap of the mechanism are not uncommon. Most of the time, cancer pain is managed on a “trial and error” basis or “concept of exclusion,” which is influenced by the pain physician’s perception. Although our understanding of cancer pain and associated molecular mechanisms has increased over the last many years, applying these concepts in the real world remains a dilemma. CONCLUSION Cancer patients suffer pain due to multiple contributing factors. Pain physician needs to look beyond the typical nociceptive and neuropathic pain, resulting in poor response in many cancer patients. Appropriate categorization of pain as nociceptive, neuropathic, nociplastic, or mixed can ensure targeted pain management. The evaluation of spiritual and psychosocial components might clarify additional areas for precise care.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
典雅的醉易完成签到,获得积分10
10秒前
冷酷紫烟完成签到,获得积分10
12秒前
深情的晓槐完成签到,获得积分10
20秒前
Aman完成签到,获得积分10
24秒前
可靠秋蝶完成签到,获得积分10
31秒前
超帅黑夜完成签到,获得积分10
35秒前
CodeCraft的应助被无限幻枫采纳,获得10
38秒前
火星上安柏完成签到,获得积分10
44秒前
50秒前
贪玩的夏真完成签到,获得积分10
56秒前
科研通AI6.4的应助被xingsixs采纳,获得10
56秒前
风中的世平完成签到,获得积分10
1分钟前
Aman完成签到,获得积分10
1分钟前
懒得起名字完成签到 ,获得积分10
1分钟前
温暖的胜完成签到,获得积分10
1分钟前
无悔完成签到 ,获得积分0
1分钟前
纯真的雁凡完成签到,获得积分10
1分钟前
柔弱的铅笔完成签到,获得积分10
1分钟前
Tracy发布了新的文献求助10
1分钟前
1分钟前
顺利夏云完成签到,获得积分10
1分钟前
xingsixs发布了新的文献求助10
1分钟前
Tracy完成签到,获得积分10
2分钟前
zwlei完成签到,获得积分10
2分钟前
腼腆的雪珊完成签到,获得积分10
2分钟前
热情的衬衫完成签到,获得积分10
2分钟前
xingsixs完成签到,获得积分10
2分钟前
危机的白凡完成签到,获得积分10
2分钟前
徐伟业完成签到 ,获得积分10
2分钟前
RetchieLi完成签到,获得积分10
2分钟前
2分钟前
无限幻枫发布了新的文献求助10
2分钟前
眼睛大的向彤完成签到,获得积分10
2分钟前
俭朴映寒完成签到,获得积分10
2分钟前
汉堡包的应助被bluemoon采纳,获得10
2分钟前
3分钟前
王磊磊0811发布了新的文献求助10
3分钟前
害羞傲安完成签到,获得积分10
3分钟前
外向夜阑完成签到,获得积分10
3分钟前
LINDENG2004完成签到 ,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158937
求助须知:如何正确求助?哪些是违规求助? 9554526
关于积分的说明 21719385
捐赠科研通 7748487
什么是DOI,文献DOI怎么找? 3427107
关于科研通互助平台的介绍 2552013
邀请新用户注册赠送积分活动 2471370